Latest Breaking News On - வாஸ் நரசிம்மன் - Page 1 : comparemela.com

Novartis Pharma AG: Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged. Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Oncology BU grew +7% (cc, +11% USD) driven by Promacta/Revolade (+18% cc), Sandoz grew +5% (cc, +11% USD) as the business is starting to stabilize Excluding prior year forward purchasing de-stocking, we estimate Q2 net sales grew +5% (cc, +10% USD), Innovative Medicines grew +7% (cc, +11% USD) and Sandoz declined -1% (cc, + 6% USD)² Q2 core¹ operating income grew +13% (cc, +18% USD) mainly driven by higher sales and favorable gross margin, partly offset by higher spend. Excluding prior year COVID-19 related forward purchasing de-stocking, we estimate core operating income increased +4% (cc, +10% USD)

United statesNew zealandGleevec glivecPromacta revoladeAfinitor votubiaExjade jadenuMoody investors serviceNovartis groupEuropean hematology associationDiovan groupSwiss exchangeUltibro groupExforge groupExchange commissionChinese national medical products administrationEuropean academy for neurology congress